| 1 |
Hürlimann E, Hofmann D, Keiser J. Ivermectin and moxidectin against soil-transmitted helminth infections. Trends Parasitol 2023;39:272-84. [PMID: 36804383 DOI: 10.1016/j.pt.2023.01.009] [Reference Citation Analysis]
|
| 2 |
Pfarr KM, Krome AK, Al-Obaidi I, Batchelor H, Vaillant M, Hoerauf A, Opoku NO, Kuesel AC. The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration. Parasit Vectors 2023;16:82. [PMID: 36859332 DOI: 10.1186/s13071-022-05581-4] [Reference Citation Analysis]
|
| 3 |
Yang Y, Ren L, Li W, Zhang Y, Zhang S, Ge B, Yang H, Du G, Tang B, Wang H, Wang J. GABAergic signaling as a potential therapeutic target in cancers. Biomed Pharmacother 2023;161:114410. [PMID: 36812710 DOI: 10.1016/j.biopha.2023.114410] [Reference Citation Analysis]
|
| 4 |
Stegemann S, Moreton C, Svanbäck S, Box K, Motte G, Paudel A. Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five. Drug Discov Today 2023;28:103344. [PMID: 36442594 DOI: 10.1016/j.drudis.2022.103344] [Reference Citation Analysis]
|
| 5 |
Kahwa I, Ayesiga I, Nakalema S, Alinaiswe R, Mbabazi R, Iqbal S. Natural products in the management of onchocerciasis. Natural Products in Vector-Borne Disease Management 2023. [DOI: 10.1016/b978-0-323-91942-5.00012-4] [Reference Citation Analysis]
|
| 6 |
Avram S, Wilson TB, Curpan R, Halip L, Borota A, Bora A, Bologa CG, Holmes J, Knockel J, Yang JJ, Oprea TI. DrugCentral 2023 extends human clinical data and integrates veterinary drugs. Nucleic Acids Res 2023;51:D1276-87. [PMID: 36484092 DOI: 10.1093/nar/gkac1085] [Reference Citation Analysis]
|
| 7 |
Frallonardo L, Di Gennaro F, Panico GG, Novara R, Pallara E, Cotugno S, Guido G, De Vita E, Ricciardi A, Totaro V, Camporeale M, De Iaco G, Bavaro DF, Lattanzio R, Patti G, Brindicci G, Papagni R, Pellegrino C, Santoro CR, Segala FV, Putoto G, Nicastri E, Saracino A. Onchocerciasis: Current knowledge and future goals. Front Trop Dis 2022;3. [DOI: 10.3389/fitd.2022.986884] [Reference Citation Analysis]
|
| 8 |
Hawryluk* NA. The Antifilarial Drug Pipeline. Human and Animal Filariases 2022. [DOI: 10.1002/9783527823413.ch18] [Reference Citation Analysis]
|
| 9 |
Mackenzie CD, Souza A, Geary TG. Diagnosis and Assessment of Human Filarial Infections: Current Status and Challenges. Human and Animal Filariases 2022. [DOI: 10.1002/9783527823413.ch5] [Reference Citation Analysis]
|
| 10 |
Ekpo UF, Eneanya OA, Nwankwo EN, Soneye IY, Weil GJ, Fischer PU, Nwaorgu OC. Persistence of onchocerciasis in villages in Enugu and Ogun states in Nigeria following many rounds of mass distribution of ivermectin. BMC Infect Dis 2022;22:832. [DOI: 10.1186/s12879-022-07811-7] [Reference Citation Analysis]
|
| 11 |
Ju T, Vander Does A, Ingrasci G, Norton SA, Yosipovitch G. Tropical parasitic itch in returned travellers and immigrants from endemic areas. J Eur Acad Dermatol Venereol 2022. [PMID: 35793476 DOI: 10.1111/jdv.18408] [Reference Citation Analysis]
|
| 12 |
Luu L, Bah GS, Okah-Nnane NH, Hartley CS, Glover AF, Walsh TR, Lian LY, Zhan B, Bottazzi ME, Abraham D, Petrovsky N, Bayang N, Tangwa B, Ayiseh RB, Mbah GE, Ekale DD, Tanya VN, Lustigman S, Makepeace BL, Graham-Brown J. Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine Onchocerca ochengi Infection Model of Human Onchocerciasis. Vaccines (Basel) 2022;10:861. [PMID: 35746469 DOI: 10.3390/vaccines10060861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 13 |
Ehrens A, Hoerauf A, Hübner MP. Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis. GMS Infect Dis 2022;10:Doc02. [PMID: 35463816 DOI: 10.3205/id000079] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 14 |
Wolstenholme AJ, Neveu C. The avermectin/milbemycin receptors of parasitic nematodes. Pesticide Biochemistry and Physiology 2022;181:105010. [DOI: 10.1016/j.pestbp.2021.105010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 15 |
Huang C, Xu R. Determination and Correlation of Moxidectin Solubility in Aqueous Cosolvents of Methanol, Ethanol, Isopropanol, and Ethylene Glycol. J Chem Eng Data. [DOI: 10.1021/acs.jced.1c00517] [Reference Citation Analysis]
|
| 16 |
Kang TR, Dinga JN, Orock AE, Monya E, Ngemenya MN. Macrofilaricidal Activity, Acute and Biochemical Effects of Three Lichen Species Found on Mount Cameroon. J Parasitol Res 2022;2022:1663330. [PMID: 35036001 DOI: 10.1155/2022/1663330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Cháves-gonzález LE, Morales-calvo F, Mora J, Solano-barquero A, Verocai GG, Rojas A. What lies behind the curtain: Cryptic diversity in helminth parasites of human and veterinary importance. Current Research in Parasitology & Vector-Borne Diseases 2022;2:100094. [DOI: 10.1016/j.crpvbd.2022.100094] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 18 |
Kaji MD, Noonan JD, Geary TG, Beech RN. Structural mechanism underlying the differential effects of ivermectin and moxidectin on the C. elegans glutamate-gated chloride channel GLC-2. Biomed Pharmacother 2022;145:112380. [PMID: 34749053 DOI: 10.1016/j.biopha.2021.112380] [Reference Citation Analysis]
|
| 19 |
The Blinding Neglected Tropical Diseases: Onchocerciasis (River Blindness) and Trachoma. Forgotten People, Forgotten Diseases 2021. [DOI: 10.1002/9781683673903.ch5] [Reference Citation Analysis]
|
| 20 |
Sunderkötter C, Wohlrab J, Hamm H. Scabies: Epidemiology, Diagnosis, and Treatment. Dtsch Arztebl Int 2021;118:695-704. [PMID: 34615594 DOI: 10.3238/arztebl.m2021.0296] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 21 |
Welsche S, Mrimi EC, Keller L, Hürlimann E, Hofmann D, Hattendorf J, Ali SM, Keiser J. Efficacy and safety of moxidectin and albendazole compared to ivermectin and albendazole co-administration in adolescents infected with Trichuris trichiura: a randomized controlled trial protocol. Gates Open Res 2021;5:106. [PMID: 34632308 DOI: 10.12688/gatesopenres.13299.2] [Reference Citation Analysis]
|
| 22 |
Ngwewondo A, Scandale I, Specht S. Onchocerciasis drug development: from preclinical models to humans. Parasitol Res 2021;120:3939-64. [PMID: 34642800 DOI: 10.1007/s00436-021-07307-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 23 |
Abraham D, Graham-Brown J, Carter D, Gray SA, Hess JA, Makepeace BL, Lustigman S. Development of a recombinant vaccine against human onchocerciasis. Expert Rev Vaccines 2021;:1-12. [PMID: 34488533 DOI: 10.1080/14760584.2021.1977125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 24 |
Welsche S, Mrimi EC, Keller L, Hürlimann E, Hofmann D, Hattendorf J, Ali SM, Keiser J. Efficacy and safety of moxidectin and albendazole compared to ivermectin and albendazole co-administration in adolescents infected with Trichuris trichiura: a randomized controlled trial protocol. Gates Open Res 2021;5:106. [DOI: 10.12688/gatesopenres.13299.1] [Reference Citation Analysis]
|
| 25 |
Bousquet-Mélou A, Lespine A, Sutra JF, Bargues I, Toutain PL. A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients. Front Pharmacol 2021;12:666348. [PMID: 34093195 DOI: 10.3389/fphar.2021.666348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 26 |
Kumar ND, ter Ellen BM, Bouma EM, Troost B, van de Pol DPI, van der Ende-metselaar HH, van Gosliga D, Apperloo L, Carpaij OA, van den Berge M, Nawijn MC, Stienstra Y, Rodenhuis-zybert IA, Smit JM. Moxidectin and ivermectin inhibit SARS-CoV-2 replication in Vero E6 cells but not in human primary airway epithelium cells.. [DOI: 10.1101/2021.05.17.444467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 27 |
Casulli A. New global targets for NTDs in the WHO roadmap 2021-2030. PLoS Negl Trop Dis 2021;15:e0009373. [PMID: 33983940 DOI: 10.1371/journal.pntd.0009373] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 28 |
Christensen SB. Natural Products That Changed Society. Biomedicines 2021;9:472. [PMID: 33925870 DOI: 10.3390/biomedicines9050472] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 29 |
Walker M, Hamley JID, Milton P, Monnot F, Kinrade S, Specht S, Pedrique B, Basáñez MG. Supporting drug development for neglected tropical diseases using mathematical modelling. Clin Infect Dis 2021:ciab350. [PMID: 33893482 DOI: 10.1093/cid/ciab350] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 30 |
Hamley JID, Blok DJ, Walker M, Milton P, Hopkins AD, Hamill LC, Downs P, de Vlas SJ, Stolk WA, Basáñez MG. What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? Trans R Soc Trop Med Hyg 2021;115:269-80. [PMID: 33515042 DOI: 10.1093/trstmh/traa193] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 31 |
Cheke RA, Little KE, Young S, Walker M, Basáñez MG. Taking the strain out of onchocerciasis? A reanalysis of blindness and transmission data does not support the existence of a savannah blinding strain of onchocerciasis in West Africa. Adv Parasitol 2021;112:1-50. [PMID: 34024357 DOI: 10.1016/bs.apar.2021.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 32 |
Jawahar S, Tricoche N, Bulman CA, Sakanari J, Lustigman S. Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis. PLoS Negl Trop Dis 2021;15:e0009064. [PMID: 33600426 DOI: 10.1371/journal.pntd.0009064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 33 |
Risch F, Ritter M, Hoerauf A, Hübner MP. Human filariasis-contributions of the Litomosoides sigmodontis and Acanthocheilonema viteae animal model. Parasitol Res 2021. [PMID: 33547508 DOI: 10.1007/s00436-020-07026-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 34 |
Tyagi R, Bulman CA, Cho-Ngwa F, Fischer C, Marcellino C, Arkin MR, McKerrow JH, McNamara CW, Mahoney M, Tricoche N, Jawahar S, Janetka JW, Lustigman S, Sakanari J, Mitreva M. An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease. Pathogens 2021;10:71. [PMID: 33466870 DOI: 10.3390/pathogens10010071] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 35 |
Hamley JI, Blok DJ, Walker M, Milton P, Hopkins AD, Hamill LC, Downs P, de Vlas SJ, Stolk WA, Basáñez M. What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?. [DOI: 10.1101/2020.10.26.20219733] [Reference Citation Analysis]
|
